文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

重新评估显示,在伴有淋巴结转移的T1b期食管腺癌手术切除标本中,浸润深度被低估。

Reassessment reveals underestimation of infiltration depth in surgical resection specimens with lymph-node positive T1b esophageal adenocarcinoma.

作者信息

Chan Man Wai, Nieuwenhuis Esther A, Meijer Sybren L, Jansen Marnix, Vieth Michael, van Berge Henegouwen Mark I, Pouw R E

机构信息

Gastroenterology and Hepatology, Cancer Center Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands.

Pathology, Amsterdam UMC Locatie AMC, Amsterdam, Netherlands.

出版信息

Endosc Int Open. 2025 Feb 5;13:a25097208. doi: 10.1055/a-2509-7208. eCollection 2025.


DOI:10.1055/a-2509-7208
PMID:40007654
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11855241/
Abstract

BACKGROUND AND STUDY AIMS: Endoscopic resection (ER) has proven effective and safe for T1 esophageal adenocarcinoma (EAC). However, uncertainty remains concerning risk-benefit return of esophagectomy for submucosal lesions (T1b). Surgical series in past decades have reported significant risk of lymph node metastasis (LNM) in T1b EAC, but these rates may be overestimated due to limitations in histological assessment of surgical specimens. We aimed to test this hypothesis by reassessing histological risk features in surgical specimens from T1b EAC cases with documented LNM. PATIENTS AND METHODS: A retrospective cross-sectional study (1994-2005) was conducted. Patients who underwent direct esophagectomy without prior neoadjuvant therapy for suspected T1b EAC with LNM were included. Additional tissue sections were prepared from archival tumor blocks. A consensus diagnosis on tumor depth, differentiation grade, and lymphovascular invasion (LVI) was established by a panel of experienced pathologists. RESULTS: Specific depth of submucosal invasion (sm1 to sm3) was not specified in 10 of 11 archival case sign-out reports. LVI status was not reported in seven of 11 cases. Following reassessment, one patient was found to have deep tumor invasion into the muscularis propria (T2). The remaining 10 of 11 patients exhibited deep submucosal invasion (sm2-3), with five showing one or more additional risk features (poor differentiation and/or LVI). CONCLUSIONS: Our findings highlight the potential for underestimating tumor depth of invasion and other high-risk features in surgical specimens. Despite the limited cohort size, our study confirmed a consistent high-risk histological profile across all cases. Caution is warranted when extrapolating LNM risk data from historic heterogeneous cross-sectional surgical cohorts to the modern ER era.

摘要

背景与研究目的:内镜下切除术(ER)已被证明对T1期食管腺癌(EAC)有效且安全。然而,对于黏膜下病变(T1b)行食管切除术的风险效益回报仍存在不确定性。过去几十年的外科手术系列报道显示T1b期EAC存在显著的淋巴结转移(LNM)风险,但由于手术标本组织学评估的局限性,这些发生率可能被高估。我们旨在通过重新评估有记录LNM的T1b期EAC病例手术标本的组织学风险特征来验证这一假设。 患者与方法:进行了一项回顾性横断面研究(1994 - 2005年)。纳入了因疑似T1b期EAC伴LNM而未接受新辅助治疗直接行食管切除术的患者。从存档的肿瘤组织块制备额外的组织切片。由一组经验丰富的病理学家对肿瘤深度、分化程度和脉管侵犯(LVI)达成共识诊断。 结果:11份存档病例报告中有10份未明确黏膜下浸润的具体深度(sm1至sm3)。11例中有7例未报告LVI状态。重新评估后,发现1例患者肿瘤深度侵犯至固有肌层(T2)。其余11例中的10例表现为黏膜下深层浸润(sm2 - 3),其中5例表现出一种或多种其他风险特征(低分化和/或LVI)。 结论:我们的研究结果凸显了手术标本中肿瘤浸润深度及其他高危特征可能被低估的可能性。尽管队列规模有限,但我们的研究证实了所有病例中一致的高危组织学特征。在将历史上异质性的横断面手术队列中的LNM风险数据外推至现代ER时代时应谨慎。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db16/11855241/31126f754448/10-1055-a-2509-7208_25117598.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db16/11855241/312c77a0f7c3/10-1055-a-2509-7208_25117596.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db16/11855241/4d35fd181823/10-1055-a-2509-7208_25117597.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db16/11855241/31126f754448/10-1055-a-2509-7208_25117598.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db16/11855241/312c77a0f7c3/10-1055-a-2509-7208_25117596.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db16/11855241/4d35fd181823/10-1055-a-2509-7208_25117597.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db16/11855241/31126f754448/10-1055-a-2509-7208_25117598.jpg

相似文献

[1]
Reassessment reveals underestimation of infiltration depth in surgical resection specimens with lymph-node positive T1b esophageal adenocarcinoma.

Endosc Int Open. 2025-2-5

[2]
Risk of lymph node metastasis in T1 esophageal adenocarcinoma: a meta-analysis.

Dis Esophagus. 2024-6-1

[3]
Submucosal invasion and risk of lymph node invasion in early Barrett's cancer: potential impact of different classification systems on patient management.

United European Gastroenterol J. 2015-12

[4]
Surgical Management of Early-Stage Esophageal Adenocarcinoma Based on Lymph Node Metastasis Risk.

Ann Surg Oncol. 2017-11-16

[5]
Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review.

World J Gastroenterol. 2013-3-7

[6]
Can the Risk of Lymph Node Metastases Be Gauged in Endoscopically Resected Submucosal Esophageal Adenocarcinomas? A Multi-Center Study.

J Gastrointest Surg. 2016-1

[7]
Inter-Observer Variability in the Interpretation of Endoscopic Mucosal Resection Specimens of Esophageal Adenocarcinoma: Interpretation of ER specimens.

J Gastrointest Surg. 2016-1

[8]
Today's Mistakes and Tomorrow's Wisdom… in the Management of T1b Barrett's Adenocarcinoma.

Visc Med. 2022-6

[9]
Management of patients with T1b esophageal adenocarcinoma: a retrospective cohort study on patient management and risk of metastatic disease.

Surg Endosc. 2016-9

[10]
Prevalence of metastasis in T1b esophageal squamous cell carcinoma: a retrospective analysis of 258 Chinese patients.

J Thorac Dis. 2016-5

本文引用的文献

[1]
Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.

Endoscopy. 2023-12

[2]
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Ann Oncol. 2022-10

[3]
Improved Clinical and Survival Outcomes After Esophagectomy for Cancer Over 25 Years.

Ann Thorac Surg. 2022-10

[4]
Long-term outcomes after endoscopic treatment for Barrett's neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period.

Gut. 2022-2

[5]
Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study.

Endoscopy. 2022-2

[6]
AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus With Dysplasia and/or Early Cancer: Expert Review.

Gastroenterology. 2019-11-12

[7]
The 2019 WHO classification of tumours of the digestive system.

Histopathology. 2020-1

[8]
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.

JAMA Oncol. 2017-9-1

[9]
Esophagectomy Following Endoscopic Resection of Submucosal Esophageal Cancer: a Highly Curative Procedure Even with Nodal Metastases.

J Gastrointest Surg. 2017-1

[10]
Management of patients with T1b esophageal adenocarcinoma: a retrospective cohort study on patient management and risk of metastatic disease.

Surg Endosc. 2016-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索